# Crinetics Pharmaceuticals - audited company dossier

**Document Header**
- Company: Crinetics Pharmaceuticals (CRNX)
- Date: 2025-08-25
- Model: claude-opus-4-1-20250805
- Prompt: Company Dossier v. 2.2

**1) Executive Summary**

Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead asset, paltusotine (PALSONIFY™), is a once-daily oral SST2 agonist pending FDA approval for acromegaly with a PDUFA date of September 25, 2025, while atumelnant, an oral ACTH antagonist, recently reported positive Phase 2 results in congenital adrenal hyperplasia (CAH).

The investment thesis centers on the transformational potential of converting injectable endocrine therapies to oral formulations, with bulls viewing paltusotine as a paradigm shift in acromegaly treatment worth substantial peak sales potential, while bears question commercial execution risk, competitive threats from Neurocrine's approved CAH drug crinecerfont, and the $340-370M annual burn rate [7] ahead of first revenues.

**2) Key developments (last ~12M)**

| Date | Event | Interpretation |
|---|---|---|
| 2024-10-10 | Completed $575M public offering at $50/share [1] | Strong institutional support; extends runway to 2029 |
| 2024-12-30 | FDA accepted paltusotine NDA with priority review, PDUFA Sept 25, 2025 [2] | De-risked regulatory path; no AdCom required |
| 2025-01-10 | Positive Phase 2 topline results for atumelnant in CAH: 100% achieved A4<ULN, 90% reduction sustained [3] | Second pipeline asset validated; competitive with Neurocrine |
| 2025-02-27 | Reported $1.4B cash position as of Dec 31, 2024 [4] | Well-funded through multiple pivotal trials and launch |
| 2025-03-12 (publication date) | Phase 2 carcinoid syndrome: 60% reduction in bowel movements, 61% in flushing [5] | Expanded paltusotine opportunity beyond acromegaly |
| 2025-03-19 (publication date) | PATHFNDR-2 Phase 3: 56% achieved IGF-1 ≤1.0×ULN vs 5% placebo (p<0.0001) [6] | Pivotal efficacy confirmed in treatment-naïve patients |
| 2025-08-07 | Q2 2025: $1.2B cash, $115.6M quarterly burn, EMA validated MAA for paltusotine [7] | EU expansion potential; burn rate increasing with commercialization |

**3) Catalysts (next ~12M)**

| Expected date | Event | Context & potential impact (↑ / ↓) |
|---|---|---|
| 2025-09-25 | FDA PDUFA decision for paltusotine in acromegaly | Approval transforms company to commercial-stage; $500M+ peak sales opportunity (↑) |
| 2Q25 | First patient enrolled in Phase 3 CAREFNDR trial for carcinoid syndrome [4] | Expands paltusotine TAM to $300M+ market (↑) |
| 2025 | Initiate Phase 3 atumelnant in adult CAH and Phase 2b/3 in pediatric CAH [3] | Entering $1B+ CAH market against Neurocrine's crinecerfont (↑/↓) |
| 1H26 | EMA decision on paltusotine MAA [7] | EU approval adds ~40% to addressable market (↑) |
| 2026-06-26 | R&D Day featuring CRN09682 (NET), TSH antagonist (Graves'), SST3 agonist (PKD) [8] | Pipeline depth beyond lead programs (↑) |

**4) Programs / Pipeline**

**Paltusotine (acromegaly)**
- Indication & target population: Acromegaly in adults; ~3,000 patients in US requiring medical therapy [9]
- Scientific context on MoA: First oral selective SST2 receptor agonist; bypasses need for monthly injections by achieving sustained receptor activation with once-daily dosing [2]
- Current phase / stage: NDA under FDA review; Phase 3 complete [2]
- Study design: PATHFNDR-1 (n=112, 36-week switch from injectable SSAs); PATHFNDR-2 (n=111, 24-week treatment-naïve) [6][10]
- Clinical results: PATHFNDR-2 primary: 56% achieved IGF-1 ≤1.0×ULN vs 5% placebo (p<0.0001); Secondary: mean IGF-1 reduction -0.72×ULN; symptom days reduced from 30% to 6.2% (p<0.0001); Safety: no SAEs, most common AEs mild GI [6]
- Next clinical / regulatory milestone: FDA approval decision September 25, 2025 [2]
- Market context: $1.6B global market growing 7.7% CAGR; first oral option vs monthly injectables [11]
- Competitive Landscape: Chiasma/Chiesi's Mycapssa (oral octreotide) - FDA approved 2020, twice-daily dosing, limited uptake due to food restrictions; Ipsen's Somatuline (lanreotide) - injectable market leader, developing prolonged-release formulation; Novartis' Sandostatin LAR (octreotide) - injectable standard of care, generic competition emerging. Paltusotine differentiates with once-daily dosing, no food restrictions, and superior symptom control [11][12]

**Paltusotine (carcinoid syndrome)**
- Indication & target population: Carcinoid syndrome in NET patients; ~12,000 patients in US [5]
- Scientific context on MoA: SST2 agonism reduces hormone secretion from neuroendocrine tumors causing flushing/diarrhea [5]
- Current phase / stage: Phase 2 complete; Phase 3 CAREFNDR initiating 2Q25 [5]
- Study design: Phase 2 open-label (n=36), 8-week treatment at 40mg or 80mg daily [5]
- Clinical results: 60% reduction in excess bowel movements (>3/day baseline); 61% reduction in flushing severity; response within 2 weeks, sustained through 8 weeks; no treatment-related SAEs [5]
- Next clinical / regulatory milestone: Phase 3 CAREFNDR enrollment start 2Q25 [4]
- Market context: Limited oral options; patients require chronic symptom management [5]
- Competitive Landscape: Novartis' Sandostatin LAR - injectable standard; Ipsen's Somatuline Depot - monthly injectable; TerSera's Xermelo (telotristat) - oral but adjunctive therapy only. Paltusotine offers first oral monotherapy option [5]

**Atumelnant (congenital adrenal hyperplasia)**
- Indication & target population: Classic CAH due to 21-hydroxylase deficiency; ~30,000 patients in US/EU [3]
- Scientific context on MoA: First-in-class oral ACTH receptor (MC2R) antagonist; reduces ACTH-driven androgen overproduction at source vs current steroid suppression [3]
- Current phase / stage: Phase 2 complete; Phase 3 adult and Phase 2b/3 pediatric planned 2025 [3]
- Study design: TouCAHn Phase 2 open-label, 12-week treatment; three cohorts: 40mg (n=9), 80mg (n=9), 120mg (n=6) [3]
- Clinical results: 100% achieved A4<ULN at 2 weeks, sustained through 12 weeks; >90% A4 reduction, 97% 17-OHP reduction at 80mg; 8/13 females normalized testosterone, 6/11 resumed menses; 5/6 resolved polycythemia; no SAEs, most common AEs: headache (7/28), fatigue (5/28) [3]
- Next clinical / regulatory milestone: Phase 3 adult CAH and Phase 2b/3 pediatric initiation 2025 [3]
- Market context: $1B+ market opportunity; first new mechanism in 70+ years post-Neurocrine approval [13]
- Competitive Landscape: Neurocrine's Crenessity (crinecerfont) - FDA approved Dec 2024, first CRF1 antagonist, established first-mover advantage; Spruce's tildacerfont - CRF1 antagonist, Phase 2 results expected 4Q24; BridgeBio's BBP-631 - gene therapy discontinued. Atumelnant differentiates as ACTH antagonist with direct adrenal action vs upstream CRF1 mechanism [13][14]

**5) Financials**
- Cash: $1.2B as of June 30, 2025 [7]
- Burn rate: $95-100M per quarter (2025 guidance: $340-370M annually) [7]
- Liabilities: No disclosed convertibles or debt facilities [4][7]
- Recent capital raises: $575M at $50/share (October 2024); $350M private placement (February 2024) [1][4]
- Licensing deals: Sanwa Kagaku Kenkyusho paltusotine licensing/supply agreement (terms undisclosed) [15]

**6) Sell-Side Pulse**
- Consensus PT: $71.75 (15 analysts); range $39-100 with 10 Buy, 1 Hold, 0 Sell ratings [16]
- Recent upgrades: HC Wainwright $81 (Jan 2025); Cantor Fitzgerald raised to $100 from $90 maintaining Overweight [16]
- Core thesis: Transformational oral platform addressing $3B+ combined TAM; paltusotine de-risked with near-term approval; multiple shots on goal with atumelnant providing second leg of growth [16]

**7) Bull / Bear Views**

| Bull points (▲) | Bear points (▼) |
|---|---|
| First oral acromegaly drug with clear efficacy/convenience advantages over injectables | No commercial infrastructure; launch execution risk against entrenched competitors |
| $1.2B cash runway to 2029 supports multiple pivotal programs without dilution | $340-370M annual burn rate with no product revenue until late 2025 at earliest |
| Two Phase 3-ready programs (paltusotine, atumelnant) de-risks platform | Neurocrine's crinecerfont approval creates formidable CAH competitor with first-mover advantage |
| 56% IGF-1 control rate validates paltusotine efficacy in treatment-naïve patients | Mycapssa precedent shows oral acromegaly adoption challenges despite approval |
| No FDA AdCom required suggests high regulatory confidence | Limited pricing power in rare disease without outcomes differentiation |
| Expanding pipeline with NET, Graves', PKD programs showing platform productivity | Concentrated risk in endocrine space vulnerable to therapeutic advances |

**8) Investment View / Takeaways**

Crinetics represents a compelling late-stage biotech with near-term commercial catalyst and platform validation opportunity. The September 2025 paltusotine PDUFA serves as a binary event that could establish the company's oral endocrine platform credibility. With strong Phase 3 data, no AdCom requirement, and differentiated once-daily profile versus Mycapssa's twice-daily dosing, approval probability appears high. The $1.2B cash position provides ample runway through multiple value inflection points including EU approval, carcinoid syndrome Phase 3, and dual CAH studies. While commercial execution remains unproven and Neurocrine's CAH approval creates competitive headwinds, the combination of near-term revenue potential, validated platform technology, and multiple pipeline shots positions CRNX as an attractive risk/reward for investors comfortable with binary regulatory events and launch execution risk.

**Sources**

Primary Sources:
1. Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock. Crinetics Pharmaceuticals. https://www.globenewswire.com/news-release/2024/10/09/2960215/0/en/Crinetics-Pharmaceuticals-Announces-Pricing-of-Upsized-Public-Offering-of-Common-Stock.html. Accessed 2025-08-25
2. Crinetics Announces FDA Acceptance Of New Drug Application For Paltusotine For Adult Patients With Acromegaly. Crinetics Pharmaceuticals. https://crinetics.com/crinetics-announces-fda-acceptance-of-new-drug-application-for-paltusotine-for-adult-patients-with-acromegaly/. Accessed 2025-08-25
3. Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH). Crinetics Pharmaceuticals. https://www.globenewswire.com/news-release/2025/01/10/3007539/0/en/Crinetics-Announces-Positive-Topline-Results-From-Phase-2-Trial-of-Atumelnant-in-Congenital-Adrenal-Hyperplasia-CAH.html. Accessed 2025-08-25
4. Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update. Crinetics Pharmaceuticals. https://www.globenewswire.com/news-release/2025/02/27/3034312/0/en/Crinetics-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html. Accessed 2025-08-25
5. Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome. Crinetics Pharmaceuticals. https://www.globenewswire.com/news-release/2024/03/12/2845006/0/en/Crinetics-Announces-Positive-Topline-Results-from-Phase-2-Trial-of-Paltusotine-for-the-Treatment-of-Carcinoid-Syndrome.html. Accessed 2025-08-25
6. Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients. Crinetics Pharmaceuticals. https://www.globenewswire.com/news-release/2024/03/19/2848371/0/en/Crinetics-Once-Daily-Oral-Paltusotine-Achieved-the-Primary-and-All-Secondary-Endpoints-in-the-Phase-3-PATHFNDR-2-Study-in-Acromegaly-Patients.html. Accessed 2025-08-25
7. Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update. Crinetics Pharmaceuticals. https://www.globenewswire.com/news-release/2025/08/07/3129665/0/en/Crinetics-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html. Accessed 2025-08-25

Secondary Sources:
8. Drug Development Research Pipeline. Crinetics Pharmaceuticals. https://crinetics.com/pipeline/. Accessed 2025-08-25
9. Paltusotine (oral SST2 Agonist) Acromegaly Carcinoid Syndrome. Crinetics Pharmaceuticals. https://crinetics.com/pipeline/paltusotine-acromegaly-nets-carcinoid-syndrome/. Accessed 2025-08-25
10. Crinetics' Once-Daily Oral Paltusotine Achieved The Primary And All Secondary Endpoints In The Phase 3 PATHFNDR-1 Study. Crinetics Pharmaceuticals. https://crinetics.com/crinetics-paltusotine-achieved-primary-and-secondary-endpoints-in-phase-3-pathfndr-1-acromegaly-study/. Accessed 2025-08-25
11. Acromegaly Treatment Market Size, Share, Price. Market.us. https://market.us/report/acromegaly-treatment-market/. Accessed 2025-08-25
12. Chiasma carries new oral acromegaly treatment, Mycapssa, to FDA approval. BioWorld. https://www.bioworld.com/articles/436078-chiasma-carries-new-oral-acromegaly-treatment-mycapssa-to-fda-approval. Accessed 2025-08-25
13. FDA Approves New Treatment for Congenital Adrenal Hyperplasia. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-congenital-adrenal-hyperplasia. Accessed 2025-08-25
14. Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal Hyperplasia Treatment Market. DelveInsight. https://www.prnewswire.com/news-releases/neurocrine-biosciencess-crinecerfont-is-set-to-transform-the-congenital-adrenal-hyperplasia-treatment-market--delveinsight-302262193.html. Accessed 2025-08-25
15. Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update. Crinetics Pharmaceuticals. https://www.globenewswire.com/news-release/2025/05/08/3077689/0/en/Crinetics-Pharmaceuticals-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Update.html. Accessed 2025-08-25
16. Analyst Consensus - CRNX. WallStreetZen. https://www.wallstreetzen.com/stocks/us/nasdaq/crnx/stock-forecast. Accessed 2025-08-25